Last reviewed · How we verify
Buccal insulin spray
Insulin receptor agonist
Insulin receptor agonist Used for Type 1 diabetes, Type 2 diabetes.
At a glance
| Generic name | Buccal insulin spray |
|---|---|
| Also known as | Generex Oral-lynTM (oral, buccal insulin spray) |
| Sponsor | Generex Biotechnology Corp. |
| Drug class | Insulin analog |
| Target | Insulin receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
Buccal insulin spray works by activating the insulin receptor on the surface of cells, mimicking the action of naturally occurring insulin.
Approved indications
- Type 1 diabetes
- Type 2 diabetes
Common side effects
- Hypoglycemia
- Local irritation
Key clinical trials
- Intranasal vs Buccal vs Intramuscular Midazolam for the Home and Emergency Treatment of Acute Seizures (PHASE4)
- Treatment Use of Generex Oral-lyn™ in Patients With Diabetes
- Active Comparator Study of Generex Oral-lyn™ Spray and Injected Human Insulin (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Buccal insulin spray CI brief — competitive landscape report
- Buccal insulin spray updates RSS · CI watch RSS
- Generex Biotechnology Corp. portfolio CI